IRAK

IRAK Related Products (51):

By Effects:	Inhibitors (37) Modulator (1) Degraders (9) Ligands (2)

Cat. No.	Product Name	Effect	Purity

HY-13329

IRAK-1-4 Inhibitor I	Inhibitor	99.90%
IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor-associated kinase 1/4 (IRAK 1/4) with IC₅₀s of 0.2 μM and 0.3 μM, respectively.

HY-153368

Zomiradomide	Degrader	98.04%
Zomiradomide is an orally active PROTAC degrader for IRAK4 (DC₅₀=6 nM), thereby inhibiting the NF-κB signaling pathway. Zomiradomide acts also as a molecular glue, recruiting Ikaros and Aiolos, and mediating their degradation (DC₅₀ for Ikaros is 1 nM), thereby activating the type I IFN signaling pathway. (Pink: target protein ligand PROTAC IRAK4 ligand-5 (HY-168311), Blue: E3 ligase ligand Thalidomide-4-Br (HY-W039116), Black: linker (HY-168313))

HY-147264

Edecesertib	Inhibitor	99.86%
Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research.

HY-142662A

PROTAC IRAK3 degrade-1 formic	Degrader	99.26%
PROTAC IRAK3 degrader-1 formic is a potent and selective IRAK3 degrader with a DC₅₀ of 0.002 μM. PROTAC IRAK3 degrader-1 formic induces proteasome-dependent degradation of IRAK3 via ternary complex formation with IRAK3 and CRBN. PROTAC IRAK3 degrader-1 formic can be used for cancer research.

HY-151363

IRAK4-IN-21	Inhibitor	99.94%
IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC₅₀ values of 5 and 56 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis.

HY-180579

IRAK4-IN-33	Inhibitor
IRAK4-IN-33 (Compound 22) is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC₅₀ 0.36 nM. IRAK4-IN-33 can block the pro-inflammatory signaling pathway mediated by IRAK4 and inhibit the release of TNFα and IFNα. IRAK4-IN-33 shows weak inhibition for hERG channel (IC₅₀ > 30 μM). IRAK4-IN-33 can be used for the research of inflammation and immunology, such as rheumatoid arthritis.

HY-W014223

2,4′-Dihydroxybenzophenone	Inhibitor	98.00%
2,4′-Dihydroxybenzophenone (Ultraviolet absorber UV-0) occupies the hydrophobic pocket of MD2 and blocks the dimerization of TLR4. 2,4′-Dihydroxybenzophenone inhibits the LPS induced mtROS production, and LPS induced inflammatory response by downregulating pro-inflammatory mediators and decreasing the expression of MyD88, p-IRAK4, and NF-κB. 2,4′-Dihydroxybenzophenone is also a UV absorber.

HY-P5432

IRAK-4 Peptide substrate		99.87%
IRAK-4 Peptide substrate (IRAK-1 (360-380)) is a biological active peptide. (This is a substrate peptide for Interleukin-1 Receptor-Associated Kinase (IRAK) 4)

HY-101922

IRAK4-IN-1	Inhibitor	99.62%
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC₅₀ of 7 nM.

HY-W722277A

LCC-12 formate	Inhibitor	99.9%
LCC-12 (formate) is a copper (II) chelator and a derivative of the biguanide metformin (HY-B0627). LCC-12 (formate) reduces its hydrogen peroxide-dependent oxidation of NADH to NAD+. LCC-12 (formate) reduces IL-1β, IL-2, IL-6, IL-8, and TNF-α levels, as well as JAK2, STAT2, and IL-1 receptor-associated kinase 4 (IRAK4) levels in primary human cytokine-activated monocyte-derived macrophages (MDMs). LCC-12 (formate) reduces the number of CD80+ and CD86+ cytokine-activated MDMs. LCC-12 LCC-12 (formate) improves survival in a mouse model of sepsis induced by LPS or cecal ligation and puncture.

HY-130253

IRAK4-IN-6	Inhibitor	99.30%
IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC₅₀ of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma.

HY-13277

IRAK inhibitor 3	Modulator	98.86%
IRAK inhibitor 3 is an interleukin-1 (IL-I) receptor-associated kinase (IRAK) kinase modulator extracted from patent WO2008030579 A2.

HY-148274

KTX-582	Inhibitor	98.65%
KTX-582 is a potent IRAK4 degrader with DC₅₀ values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88^MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model.

HY-153673

PROTAC IRAK4 degrader-8	Inhibitor	99.70%
PROTAC IRAK4 degrader-8 (Compound 2) is a PROTAC IRAK4 degrader (IC₅₀: 15.5 nM). PROTAC IRAK4 degrader-8 degrades IRAK4 in THP-1 cells (DC₅₀: 1.8 nM)。PROTAC IRAK4 degrader-8 also inhibits L-6 production in human whole blood and LPS-induced human PBMC cells, with IC₅₀s of 246 nM and 2.2 nM respectively.

HY-153673

PROTAC IRAK4 degrader-8	Degrader	99.70%
PROTAC IRAK4 degrader-8 (Compound 2) is a PROTAC IRAK4 degrader (IC₅₀: 15.5 nM). PROTAC IRAK4 degrader-8 degrades IRAK4 in THP-1 cells (DC₅₀: 1.8 nM)。PROTAC IRAK4 degrader-8 also inhibits L-6 production in human whole blood and LPS-induced human PBMC cells, with IC₅₀s of 246 nM and 2.2 nM respectively.

HY-151365

IRAK4-IN-22	Inhibitor	99.44%
IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC₅₀ values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis.

HY-172590

LZ-07	Degrader	98.27%
LZ-07 is a IRAK4 PROTAC degrader (DC₅₀ = 1.14 nM). LZ-07 leads to marked suppression of cytokines including IL-6, IL-1β, TNF-α, and IL-10 upon degradation of IRAK4. LZ-07 can be studied in research for autoimmune diseases (Pink: IRAK4 ligand (HY-172591); Blue: CRBN ligand (HY-34590); Black: linker (HY-B0149); CRBN ligand + linker: HY-172593).

HY-145483A

KT-474 hydrochloride	Degrader	≥98.0%
KT-474 (KYM-001; PROTAC IRAK4 degrader-7) hydrochloride is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups.

HY-13275

IRAK inhibitor 1	Inhibitor	99.83%
IRAK inhibitor 1 is a potent IRAK-4 inhibitor with IC₅₀ of 216 nM, is poorly active against JNK-1 and JNK-2 with IC₅₀ of 3.801 μM, and >10 μM, respectively.

HY-13280

IRAK inhibitor 6	Inhibitor	99.75%
IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor associated kinase 4 (IRAK-4) with IC₅₀ of 160 nM.

Name
Email *

	Sorry, but the email address you supplied was invalid.